Mankind’s journey began in 1995 with only 53 Medical Representatives and Managers. Today, Mankind is one of the top 5 leading pharmaceutical companies in India, with a field force of 1600 Medical Representatives and 400 Managers.
Mankind Pharma achieved a turnover of Rs. 9700 million for the fiscal year 2013-14 with a growth of 13%. It contributed 35% of Mankind Group of Company’s sales which was Rs. 27800 million in 2013-14.
Mankind Pharma focuses on a variety of therapeutic segments such as Cardiovascular, Antibiotics, Gastro-Intestinal, Anti-Allergic, Antifungal, Nutritional, NSAID’s and Gynaecological.
Mankind has launched many innovative and successful products such as Noragyl, Ranispas, Ranidomin the Indian market and economical brands like Nurokind, Moxikind and Telmikind.
The total net worth of Mankind Pharma’s products is as follows: Moxikind (Rs. 1400 million), Zenflox (Rs. 820 million), Amlokind (Rs. 810 million), Nurokind (Rs. 630 million) and Telmikind (Rs. 550 million).
Mankind Pharma gives equal emphasis to quality and compliance. All our manufacturing processes are adhere to GMP guidelines to ensure excellent quality standards.
Technology and Research and Development play a vital role in creating quality healthcare products. Mankind manufactures a wide range of dosage forms including oral solids, oral liquids, soft gelatin capsules and injectables. It also creates products that require specialized conditions such as controlled-release pharmaceutical products, controlled humidity and temperature conditions.
Mankind Pharma’s mission is to improve the quality of life, to continue to be recognized as a reliable provider of healthcare products and nurture innovation that leads to collective excellence.
Established in the year 2002, Discovery Mankind is one of the flagship divisions of Mankind Pharma, with a turnover of Rs. 8000 million.
Driven by the ethos of ‘Serving Life’, the strength of the Discovery Mankind is rooted in its dynamic team which has helped create a strong presence across the country.
Discovery Mankind’s product portfolio includes Anti-Diabetic, Anti-infective, Nutritionals, Gynaecological, Anti-fungal, Anti-allergic and Gastro-intestinal drugs. With major focus on Anti-Diabetic, Discovery Mankind offers a product-mix ranging from Monotherapy to Combination therapy that caters to the medical needs of patients with products like Glykind-M, Glimestar, Glucomust and Voglistar Range.
Discovery Mankind provides affordable products of excellent quality that are best-in-class in their respective segments. Some of the first ranked brands belonging to Discovery Mankind are Mahaflox, Lizoforce, Candiforce, Fynal-OZ, Monticope and Nurokind Plus.
The price penetration policy is the driving force behind Discovery Mankind’s market success. By keeping profit margins at a minimum, it has extended the benefits to patients by establishing a mutual platform of trust and solidarity between prescribers and products. Brands such as Health-OK, Orthoboon and Nurokind-Next have been widely acknowledged across various medical fraternities.
Discovery Mankind is committed to providing accessible healthcare to people by assuring world-class support in terms of treatment and medicines across therapeutic segments.
Future Mankind began in 2007 with a meagre turnover of Rs. 29.2 million. It reached a turnover of Rs. 2260 million with a growth of 28% in 2013-14 and aims to achieve a turnover of Rs.3000 million in 2015.
Future Mankind is driven by innovation to provide quality pharmaceutical products at affordable prices with exclusive packaging and promote a healthy and active lifestyle.
Currently, Future Mankind has a best-in-class multi-cultural field force of 1200 across India with widespread network of stockists ensuring a strong presence across the nation.
Future Mankind specializes in manufacturing products for Neuropsychiatry and Dentistry. Future Mankind’s product portfolio includes prescription medicines ranging across therapeutic areas such as Anti-infective, Anti-allergic, Nutritional and Gastrointestinal formulations.
Top Products like Nurokind (Rs. 360 million), Clonafit (Rs. 160 million), Zady (Rs. 110 million), Thermokind (Rs. 100 million), Histafree (Rs. 95 million), Ranidom (Rs. 90 million), Flora (Rs. 80 million) contribute to the success of Future Mankind.
Its latest product, Zincolife Plus Sachet, has set new standards of excellence in the pharmaceutical market with its unique composition. Future Mankind will continue to perform its best in the pharmaceutical market, progressing towards a better, healthier and happier world.
Special Mankind, one of Mankind’s fastest growing divisions, is renowned for providing OTC and consumer products that include top-selling brands across several categories.
Today, Manforce Condom, PregaNews and Unwanted-72 are the flagship brands which hold the top position in the OTC segment. Adding to Special Mankind’s strength are products such Heal-O-Kind, Kaloree 1, Gas-O-Fast, Adiction Deodorant, Manforce Tablet and Staylong Gel.
Special Mankind’s latest launch - Heal-O-Kind –is an all-rounder ointment that heals all types of injuries. Heal-O-Kind is formulated with Nanofine technology and antibacterial action which absorbs quickly into the skin to allowing faster and scar-less healing.
The driving force behind Special Mankindis the marketing initiative and price penetration strategy. Special Mankind has positioned its brands to be economical for consumers, forcing other companies to cut their prices as well.
Special Mankind’s marketing strategy is directed towards making a strong connection between product and consumer. Consumer attitudes towards brands and products are enhanced by celebrity endorsements. Special Mankind’s marketing initiative enlisted Sunny Leone and Shilpa Shetty as brand ambassadors who have been able to build a strong consumer connect. Marketing on social media for youth-centric products, below-the-line promotions on buses, trains and hoardings and film integration have proved to be successful.
Special Mankind has an aggressive sales and distribution strategy that involves high penetration in Tier-II and Tier-III towns along with metro cities. Its distribution infrastructure continues to grow, venturing into new retail chains and centralized stores.
Special Mankind OTC division has over 900 dedicated field personnel that cover all retail outlets accounting to a major share of volume for its OTC brands.
With cutting-edge R&D centre, GMP-certified manufacturing units and marketing excellence, Special Mankind continues to provide the best quality products in FMCG and OTC categories.
Vet Mankind is a division of Mankind Pharma that focusses on the veterinary industry to promote the future of animal healthcare. Initially, Vet Mankind stepped into the dairy industry with medicines and feed supplements for cattle that eventually raised the popularity of its economical and quality products amongst livestock owners and dairy farms.
After achieving success in the dairy industry, Vet Mankind ventured into pet and poultry healthcare with innovative products such as nutritional supplements, antibiotics, anti-fungal shampoos, anti-tick medications, and dry shampoos.
Today, Vet Mankind has a total field force of approximately 600, which includes 500 VSOs and 100 Managers and a stockist network spread across the country. Vet Mankind achieved a turnover of Rs.900 million in fiscal year 2013-14 with a growth of 29%, and is set to achieve Rs.1300 million in the next financial year.
Vet Mankind has manufactured several innovative and unique products like Nurokind-Plus Vet Injection, Moxikind-ClavInjection, Bandykind Plus Bolus, Fendikind Plus Bolus, Megablota Suspension, and Enerdyna Liquid. To meet the growing needs of the industry, Vet Mankind will soon launch a range of products that comprises poultry feed supplements, immunity modulators, growth promoters, and laxatives.
After carving a niche in the domestic market, Vet Mankind has also entered the international market by starting operations in Nepal through proper distribution channels and a skilled field force.
Vet Mankind strives to improve business processes and work standards by focussing on providing marketing tools and technical training the field force, as well as improving coverage and culture to be in sync with Mankind’s philosophy of ‘Serving Life’.